Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by NamesJebon Oct 04, 2020 2:34pm
151 Views
Post# 31664607

RE:RE:RE:No results = no confidence here...funken share price down!

RE:RE:RE:No results = no confidence here...funken share price down!
luvhorses wrote: It's not about how many patients are enrolled in the trials...it's about RESULTS, RESULTS, RESULTS!!!

$hit on a stick, they can have 13000 people on their trial list or 130 000  but at the end of the day, without results, this isn't going anywhere but down!!! Now if the results are + then you got me....tis will move big time!
But, you need to ask yourself....how long before results are released??
Funken didn't get it right when they were in KOREA...so, what makes you think that they're going to fast track results from the States????


Okay so let's start with your first point. It specifically does matter how many people are enrolled. Since we know we need 150 patients for the 2b portion and we're at 113+ with the rate of enrollment increasing it means we're getting closer to completion. Once completed they will analyze data and release the results in q4 as they've stated 907 times. As for your 2nd point there probably will never be data released from South Korea as there just are not enough people who meet the clinical trial requirements who reside in the specific locations that are running the trial. Now lastly, I'm uncertain if this is a joke or if you don't understand how stocks actually work. But if we waited for the results first, then purchased this stock, there would be no money to make (or much less). The entire point is it's an educated guess based on research and your own due diligence with the possibility of exponential gains. I think I speak for everyone here when I say your repetitive spewing of uninformed fecal matter from the mouth is getting old.
<< Previous
Bullboard Posts
Next >>